Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND Cytokinetics, IncorporatedDecember 14, 2020 GMT SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data relating to the impact of patient characteristics on treatment effect in FORTITUDE-ALS, the Phase 2 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), were presented at the 31st Inte...
Source: apnews.com